Founded in 2019 as a spinout from Therachon, VectivBio is led by a world-class team with expertise in rare diseases. They aim to bring transformational medicines to patients with serious rare conditions, focusing on diseases with well-defined biology. Currently, they are advancing their lead program for Short Bowel Syndrome while building a portfolio of rare disease medicines. Based in Basel, Switzerland, VectivBio is committed to improving the lives of patients and their families by providing best-in-disease therapies.